CHEK1 and cancer: From a cancer therapeutics perspective, the promising tumor growth inhibition observed in our xenograft study support the evaluation of BOLD-100 in combination with novel ATR inhibitors or other inhibitors of the replication stress response (e.g., CHK1 inhibitors) in clinical trials for patients with metastatic BRAFMT colorectal cancer.